High-Purity Methyl Ester Intermediate for Kinase Inhibitor Synthesis
Advancing oncology research with a specialized intermediate for kinase inhibitor development.
Get a Quote & SampleProduct Core Value
Methyl 8-fluoro-3-(2-methoxy-5-(trifluoromethyl)phenyl)-2-oxo-1,2,3,4-tetrahydroquinazoline-4-acetate
This high-purity chemical intermediate is essential for the synthesis of advanced kinase inhibitors and anticancer agents. Its unique molecular structure, featuring trifluoromethyl and methoxy groups, significantly enhances lipophilicity and optimizes target binding affinity, crucial for effective drug development.
- Leverage advanced medicinal chemistry with our high-purity chemical intermediate, critical for synthesizing kinase inhibitors.
- Accelerate oncology drug development by utilizing this key intermediate in the creation of novel anticancer agents.
- Explore EGFR/VEGFR inhibitor research pathways with a compound designed for structure-activity optimization.
- Benefit from the enhanced lipophilicity and target binding affinity provided by the trifluoromethyl and methoxy groups in this quinazoline derivative.
Product Advantages
Purity and Precision
Achieve superior results in your synthesis processes with a CAS 917389-21-0 compound boasting ≥97% purity, supporting high-precision medicinal chemistry.
Enhanced Bioavailability
The trifluoromethyl and methoxy substitutions in this advanced pharmaceutical synthesis building block contribute to improved lipophilicity, aiding drug absorption and efficacy.
Targeted Therapeutic Development
Facilitate the development of targeted cancer therapeutics by employing this specialized intermediate in your oncology research programs.
Key Applications
Oncology Drug Discovery
Essential for synthesizing novel kinase inhibitors and anticancer agents used in the fight against various cancers.
Medicinal Chemistry Research
Supports structure-activity relationship studies and optimization of lead compounds in drug discovery.
EGFR/VEGFR Inhibitor Development
A key building block for researchers developing targeted therapies that inhibit growth factor receptors.
Pharmaceutical Intermediate Synthesis
Serves as a critical component in the multi-step synthesis of complex pharmaceutical compounds.